Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?

被引:4
|
作者
Boerner, Thomas [1 ]
Zambirinis, Constantinos [1 ]
Gagniere, Johan [1 ,4 ,5 ]
Chou, Joanne F. [2 ]
Gonen, Mithat [2 ]
Kemeny, Nancy E. [3 ]
Cercek, Andrea [3 ]
Connell, Louise C. [3 ]
Kingham, Thomas P. [1 ]
Allen, Peter J. [1 ,6 ]
Balachandran, Vinod P. [1 ]
Drebin, Jeffrey [1 ]
Jarnagin, William R. [1 ]
D'Angelica, Michael, I [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[4] Clermont Auvergne Univ, Univ Hosp Clermont Ferrand, Dept Digest & Hepatobiliary Surg, Clermont Ferrand, France
[5] Clermont Auvergne Univ, U1071 Inserm, Clermont Ferrand, France
[6] Duke Univ, Dept Surg, Durham, NC USA
基金
美国国家卫生研究院;
关键词
HEPATIC ARTERIAL INFUSION; RANDOMIZED PHASE-III; COLON-CANCER; POOLED ANALYSIS; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; RESECTION; SURVIVAL; COMBINATION;
D O I
10.1016/j.hpb.2020.08.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. Methods: A retrospective analysis of patients with early CLM ( 12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan?Meier methods and Cox proportional hazards models. Results: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44?0.94, p = 0.022) and allcause mortality (HRadj: 0.54, 95%CI:0.36?0.81, p = 0.003) compared to Surgery alone patients. Largest tumor 5 cm (HRadj: 2.03, 95%CI: 1.41?2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29?2.89, p = 0.002) were independently associated with worse OS. Background: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. Methods: A retrospective analysis of patients with early CLM (<12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan-Meier methods and Cox proportional hazards models. Results: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44-0.94, p = 0.022) and all cause mortality (HRadj: 0.54, 95%CI:0.36-0.81, p = 0.003) compared to Surgery alone patients. Largest tumor >5 cm (HRadj: 2.03, 95%CI: 1.41-2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29-2.89, p = 0.002) were independently associated with worse OS. Conclusion: Adjuvant HAIC + Sys after resection of early CLM that occur after chemotherapy for node positive primary is associated with improved outcomes.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 50 条
  • [31] Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence
    Piercey, Oliver
    Wong, Hui-Li
    Leung, Clara
    To, Yat Hang
    Heong, Valerie
    Lee, Margaret
    Tie, Jeanne
    Steel, Malcolm
    Yeung, Justin M.
    McCormick, Jacob
    Gibbs, Peter
    Wong, Rachel
    CLINICAL COLORECTAL CANCER, 2024, 23 (01) : 95 - 103.e3
  • [32] The efficacy of XELOX and FOLFOX adjuvant chemotherapy in stage III colorectal cancer patients with low preoperative serum albumin levels
    Chen, Po-Ming
    Lin, Chun-Yi
    Chen, Rong-Fu
    Chen, Yeh-Ku
    Chu, Pei-Yi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (02): : 3162 - 3168
  • [33] Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer
    Malesci, Alberto
    Bianchi, Paolo
    Celesti, Giuseppe
    Basso, Gianluca
    Marchesi, Federica
    Grizzi, Fabio
    Di Caro, Giuseppe
    Cavalleri, Tommaso
    Rimassa, Lorenza
    Palmqvist, Richard
    Lugli, Alessandro
    Koelzer, Viktor. H.
    Roncalli, Massimo
    Mantovani, Alberto
    Ogino, Shuji
    Laghi, Luigi
    ONCOIMMUNOLOGY, 2017, 6 (12):
  • [34] Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study
    Jalaeikhoo, Hasan
    Zokaasadi, Mohammad
    Khajeh-Mehrizi, Ahmad
    Rajaeinejad, Mohsen
    Mousavi, Seied Asadollah
    Vaezi, Mohammad
    Fumani, Hosein Kmranzadeh
    Keyhani, Manoutchehr
    Alimoghaddam, Kamran
    Ghavamzadeh, Ardeshir
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2019, 24
  • [35] Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community
    Protasio, Bruno Mendonca
    Matutino, Adriana
    Lage, Liana Valente
    Santana, Iuri
    Ramos, Ricardo
    Sabbaga, Jorge
    Capareli, Fernanda
    Saragiotto, Daniel
    Riechelmann, Rachel
    Hoff, Paulo M.
    CLINICAL COLORECTAL CANCER, 2017, 16 (01) : 65 - 72
  • [36] FOLFOX as Adjuvant Chemotherapy after Curative Resection of Distant Metastases in Patients with Colorectal Cancer
    Nozawa, Hiroaki
    Kitayama, Joji
    Sunami, Eiji
    Saito, Shinsuke
    Kanazawa, Takamitsu
    Kazama, Shinsuke
    Yazawa, Kentaro
    Kawai, Kazushige
    Mori, Ken
    Nagawa, Hirokazu
    ONCOLOGY, 2011, 80 (1-2) : 84 - 91
  • [37] Adjuvant Chemotherapy for Stage III Colon Cancer
    Taieb, Julien
    Gallois, Claire
    CANCERS, 2020, 12 (09) : 1 - 17
  • [38] Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer
    Shaib, Walid L.
    Zakka, Katerina M.
    Jiang, Renjian
    Yan, Ming
    Alese, Olatunji B.
    Akce, Mehmet
    Wu, Christina
    Behera, Madhusmita
    El-Rayes, Bassel F.
    CANCER, 2020, 126 (18) : 4136 - 4147
  • [39] Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases - A ten year study
    Karanjia, N. D.
    Lordan, J. T.
    Fawcett, W. J.
    Quiney, N.
    Worthington, T. R.
    EJSO, 2009, 35 (08): : 838 - 843
  • [40] The Optimal Duration of Adjuvant Therapy for Stage III Colon Cancer: the European Perspective
    Bregni, Giacomo
    Rebuzzi, Sara Elena
    Sobrero, Alberto
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (01)